• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

T1和T2期结直肠癌中无肿瘤芽生与低级别肿瘤芽生的预后及淋巴结转移比较

Comparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer.

作者信息

Lee Jong Yoon, Roh Mee Sook, Lee Jong Hoon, Park Seun Ja, Chang Hee Kyung, Jung Seok Won, Kim Ji Hye

机构信息

Division of Gastroenterology, Department of Internal Medicine, Dong-A University College of Medicine, Daesingongwonro 26, Seo-Gu, Busan, 49201, South Korea.

Department of Pathology, Dong-A University College of Medicine, Daesingongwonro 26, Seo-Gu, Busan, 49201, South Korea.

出版信息

Sci Rep. 2025 Jan 2;15(1):212. doi: 10.1038/s41598-024-84035-6.

DOI:10.1038/s41598-024-84035-6
PMID:39747554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11696688/
Abstract

Tumor budding is a significant prognostic factor in colorectal cancer (CRC) management and is graded as follows: 0-4 buds as low, 5-9 buds as intermediate, and > 10 buds as high. However, the specific prognostic difference between cases with 0 buds (BD0) and those with 1-4 buds (BD1) is not well established owing to a lack of comparative studies. This study aimed to examine and compare the rate of lymph node (LN) metastasis and prognosis by distinguishing between BD0 and BD1 within the low-grade category (0-4 buds) of tumor budding in submucosa (T1) and muscularis propria (T2) CRC. We retrospectively identified 223 cases of T1 and T2 CRC underwent surgery from 2015 to 2018 across three medical institutions using medical records. Pathology, including assessing tumor budding, was subsequently reconfirmed, and the recurrence and survival of patients were evaluated up to December 2023. Patients in the BD1 group exhibited a higher T stage than those in the BD0 group, accompanied by significantly increased rates of lymphovascular and perineural invasion. The prevalence of LN metastasis was 14.8%. No significant differences in LN metastasis were observed between the BD0 and BD1 groups. In a multivariate analysis exploring factors associated with LN metastasis, relevant factors included lymphatic invasion, perineural invasion, and ≥ 5 buds. There were no significant differences in 5-year survival and progression free survival rates between the BD0 and BD1 groups (P = 0.971). This study confirmed that there was no significant difference in LN metastasis or prognosis between patients with BD0 and BD1.

摘要

肿瘤芽生是结直肠癌(CRC)治疗中的一个重要预后因素,其分级如下:0 - 4个芽为低级别,5 - 9个芽为中级,>10个芽为高级。然而,由于缺乏对比研究,0个芽(BD0)的病例与1 - 4个芽(BD1)的病例之间的具体预后差异尚未明确确立。本研究旨在通过区分黏膜下层(T1)和固有肌层(T2)CRC肿瘤芽生低级别类别(0 - 4个芽)中的BD0和BD1,来检查和比较淋巴结(LN)转移率和预后。我们使用病历回顾性地确定了2015年至2018年期间在三家医疗机构接受手术的223例T1和T2 CRC病例。随后重新确认包括评估肿瘤芽生在内的病理学情况,并对患者的复发和生存情况进行评估,直至2023年12月。BD1组患者的T分期高于BD0组,同时淋巴管和神经周围侵犯率显著增加。LN转移的发生率为14.8%。BD0组和BD1组之间在LN转移方面未观察到显著差异。在一项探索与LN转移相关因素的多变量分析中,相关因素包括淋巴管侵犯、神经周围侵犯和≥5个芽。BD0组和BD1组之间的5年生存率和无进展生存率无显著差异(P = 0.971)。本研究证实,BD0和BD1患者在LN转移或预后方面没有显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/a1618cd4c2cb/41598_2024_84035_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/f3dd0de3f908/41598_2024_84035_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/2f7ff774a54e/41598_2024_84035_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/a1618cd4c2cb/41598_2024_84035_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/f3dd0de3f908/41598_2024_84035_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/2f7ff774a54e/41598_2024_84035_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a74/11696688/a1618cd4c2cb/41598_2024_84035_Fig3_HTML.jpg

相似文献

1
Comparison of the prognosis and lymph node metastasis between no tumor budding and low-grade tumor budding in T1 and T2 colorectal cancer.T1和T2期结直肠癌中无肿瘤芽生与低级别肿瘤芽生的预后及淋巴结转移比较
Sci Rep. 2025 Jan 2;15(1):212. doi: 10.1038/s41598-024-84035-6.
2
Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.在结直肠癌中引入“零肿瘤芽”类别来完善 ITBCC 肿瘤芽评分系统。
Virchows Arch. 2021 Dec;479(6):1085-1090. doi: 10.1007/s00428-021-03090-w. Epub 2021 Apr 12.
3
Should a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas?结直肠腺癌国际肿瘤芽生共识会议肿瘤芽生评分系统中是否应增加第四类?
APMIS. 2022 Sep;130(9):560-567. doi: 10.1111/apm.13253. Epub 2022 Jul 11.
4
Lymph Node Tumor Burden Correlates With Tumor Budding and Poorly Differentiated Clusters: A New Prognostic Factor in Colorectal Carcinoma?淋巴结肿瘤负担与肿瘤芽生和低分化簇相关:结直肠癌的新预后因素?
Clin Transl Gastroenterol. 2021 Mar;12(3):e00303. doi: 10.14309/ctg.0000000000000303.
5
Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival.T1 和 T2 结直肠癌患者错配修复系统和 p53 表达:淋巴结转移和生存的预测作用。
J Surg Oncol. 2014 Jun;109(8):848-52. doi: 10.1002/jso.23592. Epub 2014 Mar 13.
6
Metastatic potential in T1 and T2 colorectal cancer.T1和T2期结直肠癌的转移潜能
Hepatogastroenterology. 2005 Nov-Dec;52(66):1688-91.
7
Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer.术前活检标本中的肿瘤内芽生可预测结直肠癌患者的淋巴结和远处转移。
Mod Pathol. 2012 Jul;25(7):1048-53. doi: 10.1038/modpathol.2012.56. Epub 2012 Apr 6.
8
The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.癌症干细胞标志物(Notch1、醛脱氢酶1和CD44)在原发性结直肠癌中的预后价值
J Gastrointest Cancer. 2019 Dec;50(4):824-837. doi: 10.1007/s12029-018-0156-6.
9
Tumor Budding and Worse Pattern of Invasion Can Predict Nodal Metastasis in Oral Cancers and Associated With Poor Survival in Early-Stage Tumors.肿瘤芽生和更差的浸润模式可预测口腔癌的淋巴结转移,并与早期肿瘤的不良生存相关。
Ear Nose Throat J. 2019 Aug;98(7):E112-E119. doi: 10.1177/0145561319848669. Epub 2019 May 9.
10
Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer.用于评估黏膜下结直肠癌淋巴结转移的复合评分系统和最佳肿瘤芽计数切点。
BMC Cancer. 2022 Aug 6;22(1):861. doi: 10.1186/s12885-022-09957-8.

本文引用的文献

1
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
2
Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer.用于评估黏膜下结直肠癌淋巴结转移的复合评分系统和最佳肿瘤芽计数切点。
BMC Cancer. 2022 Aug 6;22(1):861. doi: 10.1186/s12885-022-09957-8.
3
Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.在结直肠癌中引入“零肿瘤芽”类别来完善 ITBCC 肿瘤芽评分系统。
Virchows Arch. 2021 Dec;479(6):1085-1090. doi: 10.1007/s00428-021-03090-w. Epub 2021 Apr 12.
4
Study of histopathologic parameters to define the prognosis of stage II colon cancer.用于确定II期结肠癌预后的组织病理学参数研究。
Int J Colorectal Dis. 2019 May;34(5):905-913. doi: 10.1007/s00384-019-03279-1. Epub 2019 Mar 26.
5
Tumor Budding Mismatch Repair Status in Colorectal Cancer - An Exploratory Analysis.结直肠癌中的肿瘤芽生错配修复状态——一项探索性分析
Anticancer Res. 2018 Aug;38(8):4713-4721. doi: 10.21873/anticanres.12778.
6
Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.基于 2016 年国际肿瘤芽殖共识会议(ITBCC)的结直肠癌肿瘤芽殖报告推荐建议。
Mod Pathol. 2017 Sep;30(9):1299-1311. doi: 10.1038/modpathol.2017.46. Epub 2017 May 26.
7
Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.结直肠癌中肿瘤芽生影响的系统评价和荟萃分析
Br J Cancer. 2016 Sep 27;115(7):831-40. doi: 10.1038/bjc.2016.274. Epub 2016 Sep 6.
8
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.微卫星不稳定性对结直肠癌复发模式及预后的影响。
Br J Cancer. 2016 Jun 28;115(1):25-33. doi: 10.1038/bjc.2016.161. Epub 2016 May 26.
9
Implications of mismatch repair-deficient status on management of early stage colorectal cancer.错配修复缺陷状态对早期结直肠癌治疗的影响。
J Gastrointest Oncol. 2015 Dec;6(6):676-84. doi: 10.3978/j.issn.2078-6891.2015.065.
10
Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis.基于淋巴结转移风险分层的内镜治疗后T1期结直肠癌的管理
J Gastroenterol Hepatol. 2016 Jun;31(6):1126-32. doi: 10.1111/jgh.13257.